Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Apr 17, 2017
Which Mid-Stage Biotech Can Grow Into the Next Large Cap Biotech Behemoth?
Image Source: Steven Depolo. The biotech field is on the cutting edge of scientific research. The production of new therapies often positively affects the share price of these innovative companies as long-term revenue and earnings expectations become embedded in the stock price. Let’s take a look at several mid-stage biotechs that may grow into dominant players. Mar 11, 2017
Celgene: A Hemeoncology Powerhouse
Let’s walk through the investment merits of one of the market darlings in biotech. Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late. Mar 2, 2016
Politics and the Markets
Image Source: DonkeyHotey. Inside: "The impact of the election of 2016 will be disruptive with wide-ranging implications on several key industries: defense contractors via the trajectory of defense spending, fast-food restaurants and big box retailers via minimum-wage legislation and arguably immigration reform, biotech via wide-spread opposition to existing exorbitant drug prices, healthcare via the pledges of several candidates to repeal Obamacare, insurance given the call for increasing competition between states, and implications on consumer spending given each candidate’s proposed tax plans." Oct 6, 2015
Attention to Pricing Issues Pressures Valeant
Along with the biotech industry as a whole, Valeant Pharmaceuticals has been the subject of negative publicity lately, and its shares have paid the price. Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Jul 23, 2015
Guide to Second Quarter Earnings; Big Pharma Experiencing Earnings Momentum
Abbott, Bristol-Myers, Celgene, Eli Lilly, Novartis, Roche, Valeant… Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma. Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space . The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
Image Source: Biogen. The large cap biotech industry remains mired in a downtrend trend since posting a near-term top in the summer of 2015. Growth has clearly slowed and in some cases turned negative--we review the recent earnings reports of some of the largest companies.